
Novartis’ Kisqali combo rejected by NICE for advanced breast cancer
pharmafile | April 11, 2019 | News story | Sales and Marketing |Â Â Kisqali, NHS, NICE, Novartis, pharmaÂ
Novartis’ Kisqali (ribociclib) has been rejected for use on the NHS by NICE for the treatment of advanced breast cancer, the organisation has announced.
Specifically, the drug was turned down in combination with fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer in patients who have had previous endocrine therapy.
Despite clinical data demonstrating that the drug combo improved progression-free survival compared to fulvestrant alone in treatment naĂŻve patients and in patients following endocrine treatment, data on overall survival benefit were not sufficiently mature, meaning cost-effectiveness estimates were calculated much higher than the range NICE considers an acceptable use of NHS resources.
As a result, NICE judged that the combo does not have “plausible potential to be cost-effective at the offered price” and could not recommend its use on the NHS, though noted that additional data may address the uncertainties in the provided data.
Patients in the this indication can access Verzenio (abemaciclib) with fulvestrant via the Cancer Drugs Fund, and Kisqali is recommended by NICE in combination with an aromatase inhibitor for previously untreated hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer.
Public consultation is open on the decision until 9 May 2019.
Matt Fellows
Related Content

Scotland starts newborn screening for SMA
As part of a two-year evaluation funded by the Scottish government and Novartis, Scotland will …

Under-Secretary of State for Health Innovation and Safety visits new building on University of Huddersfield’s NHIC
Dr Zubir Ahmed MP, the Under-Secretary of State for Health Innovation and Safety, has visited …

Digital mental health technologies – a valuable tool in supporting people with depression and anxiety
The potential benefits of digital mental health technology for managing depression, anxiety and stress, together …






